China Contract Research Organization (CRO) Industry Report, 2020-2026
  • Nov.2020
  • Hard Copy
  • USD $3,100
  • Pages:202
  • Single User License
    (PDF Unprintable)       
  • USD $2,900
  • Code: ZLC119
  • Enterprise-wide License
    (PDF Printable & Editable)       
  • USD $4,300
  • Hard Copy + Single User License
  • USD $3,300

The contract research organization (CRO) industry has been galloping amid the global pharmaceutical market steadily in head way, the vibrant financing in the medical and health sector, and the proliferating expenses for pharmaceutical R&D. In 2020, the world CRO market is expected to worth $69.9 billion with a year-on-year spike of 9%.

Competition ever pricks up among at least 1,100 CRO players worldwide led by LabCorp, IQVIA, Syneos, Parexel, PRA, PPD, and Charles River. In 2019, IQVIA, LabCorp and Syneos were the three leaders sweeping a combined market share of 21.5%.

CRO 1_副本.png

China’s great competitive edge over the developed countries in pharmaceutical R&D cost has allured many world-renowned pharmaceutical corporations and boosted the country’s CRO industry. With speedy development over a decade, China has been an important CRO market whose market size in 2020 will soar 10.1% on an annualized basis and reach RMB81.6 billion.

In addition to multinational giants represented by IQVIA, LabCorp, Parexel, etc., China also sees local CRO leaders including Wuxi AppTec, Pharmaron, Meidicilon, Shanghai ChemPartner, Tigermed, and Joinn Laboratories, where Wuxi AppTec with the strongest R&D strength as one of the most comprehensive service platforms integrating discovery, research and development of small-molecule chemical drugs, not only runs the China’s largest small-molecule pharmaceutical R&D service business but leads the way in global market. It enjoyed a virtually 12.3% (up 1.8 percentage points over the prior year) of the world’s CRO market in 2019.

CRO 2_副本.png

China’s CRO industry will be heading towards:
1) Mergers and acquisitions will still prevail for an industry reshuffle: Seen from the development course of multinational CRO companies, giants expand their business and sharpen edges through M&As, so do the Chinese CRO peers in recent year. In September 2020, Asymchem acquired the CRO company GoalGen for RMB30 million.
2) Chinese CRO companies have landed in the capital market: WuXi AppTec and Pharmaron were listed on the A-share and H-share markets successively. In 2019, Viva Biotech went public on the Hong Kong Stock Exchange. In 2020, HitGen was listed on the A-share market.
3) The industry gears toward vertical integration: Wuxi AppTec, for example, is able to provide customers with integrated new drug R&D and production services, which can help customers save plenty of time and costs as well as improve R&D and production efficiency. Noticeably, the players like Pharmaron, Boji Medical Biotechnological, Porton Pharma Solutions, and Shanghai ChemPartner are expanding to CMO/CDMO.

China Contract Research Organization (CRO) Industry Report, 2020-2026 highlights:
20120114.gifGlobal CRO industry (development history/environment, market size, competitive landscape, etc.);
20120114.gifChina CRO industry (development environment, status quo, market size, competition pattern, development trends, etc.);
20120114.gif13 Chinese and 8 foreign companies (revenue, business structure, CRO business, etc.)

1. Overview of Pharmaceutical Outsourcing
1.1 Definition
1.2 Classification
1.3 CRO

2. Evolution of Global CRO Industry
2.1 Development History
2.2 Development Background
2.2.1 Pharmaceutical Industry Size
2.2.2 Pharmaceutical Companies Development
2.2.3 Financing
2.2.4 Pharmaceutical R&D
2.3 Market Size
2.4 Competitive Landscape

3. CRO Industry in China
3.1 Development Environment
3.1.1 Regulation
3.1.2 Policy Environment
3.1.3 Industry Environment
3.2 Status Quo
3.3 Market Size
3.4 Competitive Landscape
3.5 Development Trend
3.5.1 The Amounting Pressure from R&D Costs Make Pharmaceutical Enterprises Rely More on CRO Companies for the Research and Development of New Drugs
3.5.2 Favorable policies and capital promote the development of local Chinese companies
3.5.3 Good Prospects Attract the Enterprises’ Access into CRO Industry
3.5.4 The Industry Heads toward Vertical Integration
3.5.5 M&A May Become the Main Way for CRO Companies to Expand
3.5.6 The Comprehensive Implementation of Consistency Assessment Brings Development Opportunities to the CRO Industry
3.5.7 Industry threshold and concentration degree rises gradually
3.5.8 Specialization and characterization are becoming ever more obvious

4. Major Chinese Companies
4.1 Wuxi AppTec
4.1.1 Profile
4.1.2 Operation
4.1.3 Revenue Structure
4.1.4 Gross Margin
4.1.5 Major Clients
4.1.6 R&D Investment
4.1.7 CRO Business
4.1.8 Development Strategy
4.2 Hangzhou Tigermed
4.2.1 Profile
4.2.2 Operation
4.2.3 Revenue Structure
4.2.4 Gross Margin
4.2.5 R&D Investment
4.2.6 Development Strategy
4.3 Guangzhou Boji Pharmaceutical
4.3.1 Profile
4.3.2 Operation
4.3.3 Revenue Structure
4.3.4 Gross Margin
4.3.5 R&D Investment
4.3.6 Development Strategy
4.4 Shanghai Meidicilon Inc.
4.4.1 Profile
4.4.2 Operation
4.4.3 Revenue Structure
4.4.4 Gross Margin
4.4.5 R&D Investment
4.4.6 Major Clients
4.4.7 Development Strategy
4.5 Porton Fine Chemicals
4.5.1 Profile
4.5.2 Operation
4.5.3 Revenue Structure
4.5.4 Gross Margin
4.5.5 R&D Investment
4.5.6 Major Clients
4.5.7 Development Strategy
4.6 Joinn Laboratories
4.6.1 Profile
4.6.2 Operation
4.6.3 Revenue Structure
4.6.4 Gross Margin
4.6.5 R&D Investment
4.6.6 Major Clients
4.6.7 Development Strategy
4.7 Pharmaron
4.7.1 Profile
4.7.2 Operation
4.7.3 Revenue Structure
4.7.4 Gross Margin
4.7.5 R&D Investment
4.7.6 Major Clients
4.7.7 Development Strategy
4.8 Obio Technology (Shanghai)
4.8.1 Profile
4.8.2 Operation
4.8.3 Revenue Structure
4.8.4 Gross Margin
4.8.5 R&D Investment
4.8.6 Major Clients
4.8.7 Development Strategy
4.9 Nanjing Huawe Medicine Technology Group Co., Ltd.
4.9.1 Profile
4.9.2 Operation
4.9.3 Major Clients
4.9.4 Main Business
4.9.5 Development Strategy
4.10 Shanghai ChemPartner
4.10.1 Profile
4.10.2 Operation
4.10.3 Revenue Structure
4.10.4 Gross Margin
4.10.5 Main Business
4.11 HitGen Inc.
4.11.1 Profile
4.11.2 Operation
4.11.3 Revenue Structure
4.11.4 Gross Margin
4.11.5 R&D Investment
4.11.6 Major Clients
4.12 BioDuro
4.12.1 Profile
4.12.2 Development Course
4.12.3 R&D Center
4.12.4 Development Dynamics
4.13 VIVA Biotech
4.13.1 Profile
4.13.2 Operation
4.13.3 Revenue Structure
4.13.4 Gross Margin
4.13.5 R&D Investment

5 Major Foreign Companies
5.1 LabCorp
5.1.1 Profile
5.1.2 Operation
5.1.3 Revenue Structure
5.1.4 CRO Business
5.1.5 Development in China
5.2.1 Profile
5.2.2 Operation
5.2.3 Revenue Structure
5.2.4 Development Strategy
5.2.5 Development in China
5.3 Parexel
5.3.1 Profile
5.3.2 Operation
5.3.3 Revenue Structure
5.3.4 Dynamics
5.3.5 Development in China
5.4 Charles River
5.4.1 Profile
5.4.2 Operation
5.4.3 Revenue Structure
5.4.4 Development in China
5.5 PPD
5.5.1 Profile
5.5.2 Operation
5.5.3 Revenue Structure
5.5.4 Development in China
5.5.5 Excel PharmaStudies
5.6 Syneos Health
5.6.1 Profile
5.6.2 Operation
5.6.3 Revenue Structure
5.6.4 CRO Business
5.6.5 Development in China
5.7 PRA
5.7.1 Profile
5.7.2 Operation
5.7.3 Revenue Structure
5.7.4 Development in China
5.8 ICON
5.8.1 Profile
5.8.2 Operation
5.8.3 Revenue Structure
5.8.4 Development in China

Classification of Pharmaceutical Outsourcing
R&D Process of New Drugs
Corresponding Relationship between New Drug R & D Process, New Drug R & D Discipline and CRO Services
New Drug R&D Cost Structure
Global Pharmaceutical Market Size, 2012-2020
Global Pharmaceutical Market Size (by Type), 2012-2020
Global Pharmaceutical Market Size, 2020-2026E
Global Pharmaceutical Market Size (by Type), 2020-2026E
TOP20 Pharmaceutical Companies by Revenue, 2018-2019
US and Europe VC Dollars and Deals by Healthcare Sectors, 2018-2020
US Healthcare Venture Capital Fundraising,2010–2020
Global Medicine R&D Expense and Drug Development Expenditure, 2010-2020
Number of New Drugs Approved by FDA, 2010-2019
Number of New Drugs Approved by FDA of Pharmaceutical Companies, 2019
R&D Input of TOP10 Global Pharmaceutical Companies, 2019
Number of Medicine under Research Worldwide, 2001-2019
Average Costs of New Drugs from R&D to Approved Launch
Cumulative Success Rate of New Drug R&D from Phase I to III
Scale and YoY Growth of Global CRO Industry, 2014-2020
Scale and YoY Growth of Global CRO Industry, 2019-2026E
Comparison between Global Major CRO Companies
Main Business of Global CRO Companies  
Market Share of Major Global CRO Companies, 2019
M&A Cases of Global Major CRO Companies
Comparison of Major Global CRO Companies by Revenue, 2014-2020
Policies on China’s CRO Industry, 2010-2020
China Pharmaceutical Market Size and % in Global Total, 2012-2020
China Pharmaceutical Market Size and % in Global Total, 2020-2026E
China VC Dollars and Deals by Healthcare Sectors, 2017-2020
China VC Dollars and Deals by Healthcare Sectors by Region, 2018-2020
Investment of China Investors in US and Europe VC Healthcare Companies, 2017-2020
Development Course of CRO Industry in China
Comparison of Pharmaceutical R&D Costs in China and Developed Countries
Cases of Multinational Pharmaceutical Enterprises’ R&D Centers in China, 2001-2020
Scale and YoY Growth of China’s CRO Industry, 2011-2020
Scale and YoY Growth of China’s CRO Industry, 2020-2026E
Layout of Major Global CRO Companies in Asia
Comparison of Major Chinese CRO Companies
Main Business of Major Chinese CRO Companies
Market Share of Major Chinese CRO Companies, 2018
Market Share of Major Chinese CRO Companies, 2019
Comparison of Major Chinese CRO Companies by Revenue, 2016-2020
Comparison of Major Chinese CRO Companies by Net Income, 2016-2020
Listing of Local Chinese CRO Companies
Layout of Chinese Companies in CRO, 2015-2020
M&A Cases of Chinese CRO Companies, 2016-2020
China's Policies on Consistency Assessment, 2012-2018
Major Business of Wuxi AppTec
Service Provided by Wuxi AppTec to Pharmaceutical Companies in New Medicine R&D Stage
Revenue and Net Income of Wuxi AppTec, 2014-2020
Revenue of Wuxi AppTec by Product, 2018-2020
Revenue of Wuxi AppTec by Region, 2018-2020
Revenue Structure of Wuxi AppTec by Region, 2014-2017
Gross Margin of Wuxi AppTec, 2015-2020
Gross Margin of Wuxi AppTec by Product, 2015-2020
Revenue from Top Ten Clients of Wuxi AppTec, 2015-2017
R&D Investment and % of Total Revenue of Wuxi AppTec, 2014-2020
IPO Raised Investment Projects of Wuxi AppTec
Revenue from CRO Business (by Sector) of Wuxi AppTec, 2014-2020
Gross Margin of CRO Business (by Sector) of Wuxi AppTec, 2014-2020
Revenue and Net Income of Tigermed, 2013-2020
Revenue of Tigermed by Business, 2014-2020
Revenue Structure of Tigermed by Business, 2014-2020
Revenue of Tigermed by Region, 2014-2020
Revenue Structure of Tigermed by Region, 2014-2020
Gross Margin of Tigermed by Business, 2014-2020
R&D Investment of Tigermed and % of Total Revenue, 2013-2020
Expansion Course of Tigermed, 2004-2020
Main Business of Boji Medical Biotechnological
Revenue and Net Income of Boji Medical Biotechnological, 2014-2020
Revenue of Boji Medical Biotechnological by Business, 2014-2020
Revenue Structure of Boji Medical Biotechnological, 2014-2020
Gross Margin of Boji Medical Biotechnological by Product, 2014-2020
R&D Investment of Boji Medical Biotechnological and % of Total Revenue, 2014-2020
IPO Project Progress of Boji Medical Biotechnological, as of 2018
Development Course of Meidicilon
Revenue and Net Income of Meidicilon, 2014-2020
Revenue of Meidicilon by Business, 2014-2020
Revenue Structure of Meidicilon by Business, 2014-2020
Revenue of Meidicilon by Region, 2014-2019
Gross Margin of Meidicilon by Business, 2014-2019
R&D Investment of Meidicilon and % of Total Revenue, 2014-2020
IPO Fund-raised Projects of Meidicilon, 2017
Top Five Clients of Meidicilon and % in Total Revenue, 2014-2019
Revenue and Net Income of Porton, 2014-2020
Revenue of Porton by Business, 2017-2020
Revenue Structure of Porton by Business, 2017-2020
Revenue of Porton by Region, 2014-2020
Revenue Structure of Porton by Region, 2014-2020
Gross Margin of Porton by Business, 2017-2020
R&D Investment of Porton and % of Total Revenue, 2014-2020
Subscription of Porton in Establishment of the Industrial Fund, 2019
Revenue from Top 5 Clients of Porton and % in Total Revenue, 2015-2019
Revenue and Net Income of JOINN Laboratories, 2014-2020
Revenue of JOINN Laboratories (by Business), 2018-2019
Revenue Structure of JOINN Laboratories (by Business), 2018-2019
Gross Margin of JOINN Laboratories, 2014-2019
Business Advantages of JOINN Laboratories
R & D Expenditure of JOINN Laboratories and % of Total Revenue, 2014-2020
Investment Projects of JOINN Laboratories by Raising Funds via IPO, 2017
JOINN Laboratories’ Revenue from Top 5 Clients and % of Total Revenue, 2014-2019
Pharmaron’s Revenue and Net Income, 2014-2020
Pharmaron’s Revenue (by Business), 2017-2020
Pharmaron’s Revenue (by Region), 2017-2019
Pharmaron’s Gross Margin, 2015-2020
Pharmaron’s Gross Margin (by Business), 2017-2019
Composition of Pharmaron’s R & D Division
Pharmaron’s Staff Structure by Division, as of June 30, 2018
Pharmaron’s M&A Cases, 2016-2017
Pharmaron’s Revenue from Top 5 Clients and % of Total Revenue, 2014-2019
Revenue and Net Income of Obio Technology (Shanghai), 2014-2019
Revenue of Obio Technology (Shanghai) by Business, 2014-2019
Revenue Structure of Obio Technology (Shanghai) by Business, 2014-2019
Gross Margin of Obio Technology (Shanghai), 2014-2019
R&D Investment of Obio Technology (Shanghai) and % of Total Revenue, 2014-2019
Revenue from Top 5 Clients of Obio Technology (Shanghai) and % in Total Revenue, 2014-2018
Organization of Huawe Medicine
Revenue and Net Income of Huawe Medicine, 2016-2020
Major Clients of Huawe Medicine
Progress of Innovation Projects of Huawe Medicine under R&D
CRO Business of Huawe Medicine 
Development Course of Shanghai ChemPartner
Equity Structure of Shanghai ChemPartner’s Subsidiaries
Revenue and Net Income of Shanghai ChemPartner, 2017-2020
Revenue of Shanghai ChemPartner (by Business), 2017-2020
Revenue Structure of Shanghai ChemPartner (by Business), 2017-2020
Gross Margin of Shanghai ChemPartner, 2017-2020
Main Content of Shanghai ChemPartner’s CRO Business
Main Content of Shanghai ChemPartner’s CMO Business
Revenue and Net Income of HitGen, 2017-2020
Revenue Breakdown of HitGen by Business, 2017-2019
Revenue Breakdown of HitGen by Region, 2017-2019
Gross Margin of HitGen, 2017-2019
R&D Investment of HitGen and % of Total Revenue, 2017-2020
R&D Progress of New Drugs with Independent Intellectual Property of HitGen, as of June 2020
New Drug Projects under Research of HitGen
Top 5 Clients of HitGen, 2017-2019
Development Course of BioDuro
R&D Center of BioDuro
Development Course of VIVIA Biotech
Revenue and Net Income of VIVIA Biotech, 2016-2020
Revenue Breakdown of VIVIA Biotech by Business, 2016-2020
Revenue Structure of VIVIA Biotech by Business, 2016-2020
Revenue Breakdown of VIVIA Biotech by Region, 2016-2020
Revenue Structure of VIVA Biotech by Region, 2016-2020
Gross Margin of VIVIA Biotech, 2016-2020
R&D Investment of VIVIA Biotech and % of Total Revenue, 2016-2020
LabCorp’s Revenue and Net Income, 2013-2020
LabCorp’s Revenue (by Division), 2013-2020
LabCorp’s Revenue Structure (by Division), 2013-2020
LabCorp’s CRO Revenue and % of Total Revenue, 2013-2020
Revenue and Net Income of IQVIA, 2014-2020
Operating Revenue of IQVIA by Region and by Business, 2017-2020
Operating Revenue Structure of IQVIA by Region and by Business, 2016-2020
Business Scope of Parexel
Revenue and Net Income of Parexel, FY2014-FY2017
Operating Revenue of Parexel (by Division), FY2014-FY2017
Operating Revenue Structure of Parexel (by Division), FY2014-FY2017
Branches of Parexel in China, as of 2017H1
Revenue and Net Income of Charles River, 2014-2020
Revenue of Charles River (by Division), 2014-2020
Revenue Structure of Charles River (by Division), 2014-2020
Revenue and Net Income of PPD, 2018-2020 
Revenue Breakdown PPD by Business, 2018-2020
Revenue Structure of PPD by Business, 2018-2020
Revenue and Net Income of Syneos, 2013-2020
Revenue of Syneos by Business, 2017-2020
Revenue Structure of Syneos by Business, 2017-2020
CRO Revenue and Growth of Syneos, 2015-2020
Revenue and Net Income of PRA, 2014-2020
Revenue Breakdown of PRA by Business, 2016-2020  
Revenue Structure of PRA by Business, 2016-2020 
M&A Course of ICON, 2000-2020
Development Course of ICON 
Revenue and Net Income of ICON, 2014-2020
Revenue of ICON by Region, 2017-2019

China Contract Research Organization (CRO) Industry Report, 2020-2026

The contract research organization (CRO) industry has been galloping amid the global pharmaceutical market steadily in head way, the vibrant financing in the medical and health sector, and the prolife...

China Human Vaccine Industry Report, 2020-2026

In China, the lot release for human vaccines plunged by 17.7% in 2018 when the production record fraud of rabies vaccines for human use, freeze-dried by Changsheng Bio-Technology was exposed. The impa...

China Pharmaceutical Distribution Industry Report, 2019-2026

The Chinese pharmaceutical distribution market has been expanding steadily over the recent years, being valued at RMB2,330.3 billion in 2019 with a year-on-year increase of 8.9%, of which the pharmace...

China Pharmaceutical Distribution Industry Report, 2019-2025

China’s pharmaceutical distribution industry has sustained steady growth over the years. In 2018, the market was worth RMB2,194.5 billion, a 9.6% rise from RMB2,001.6 billion (up by 8.4% YoY) in 2017,...

China Pharmaceutical Packaging Industry Report, 2019-2025

Being incentivized by the burgeoning pharmaceuticals industry, Chinese pharmaceutical packaging market size sustained growth rates of around 10% in recent years, and outstripped RMB100 billion in 2018...

China Blood Product Industry Report, 2018-2022

The blood product industry in China develops under stimulation of industry policies and downstream demand. The country recorded total lot release volume of 64.11 million bottles of blood products in 2...

China Pharmaceutical Distribution Industry Report, 2017-2021

The Chinese pharmaceutical distribution market has developed steadily but at a slower rate in recent years. The industry rose by 10.4% year on year to RMB1.8393 trillion in 2016 and is expected to hit...

China Blood Product Industry Report, 2017-2021

China’s blood product market size mushroomed in 2016 under the impetus of liberalization of limited-price policy, price rises in varying degrees and lot release volume growth for blood products in 201...

China Pharmaceutical Packaging Industry Report, 2016-2021

Under the impetus of the fast-growing downstream pharmaceutical industry, Chinese pharmaceutical packaging market size increased year by year at the CAGR of 11.2% during 2010-2016. From 2017 to 2021, ...

China Pharmaceutical Glass Packaging Industry Report, 2014-2017

In recent years, advances in new healthcare reform have boosted market demand from China pharmaceuticals industryand driven growth in the demand from pharmaceutical packaging industry. In 2014, the Ch...

China Vitamin Industry Report,2014-2017

China is the world's largest production base of vitamins, with vitamin C and vitamin E as its most important products, wherein vitamin C and related products account for more than 60% of its total out...

China Chemical Pharmaceutical Industry Report, 2013-2016

Chemical pharmaceutical consists mainly of chemical drug preparation and active pharmaceutical ingredient (API), and the gross margin of chemical drug preparation industry is generally higher than tha...

China Pharmaceutical Distribution Industry Report, 2013

Thanks to the continuous advancement in new medical reform, China’s pharmaceutical distribution industry has maintained a fairly rapid growth in recent years, with the sales value showed a CAGR of rou...

China Pharmaceutical Glass Packaging Industry Report, 2013-2016

Influenced by the substitution of plastic, aluminum foil and other new packaging materials as well as the declining packaging material purchase prices incurred by the medical reform, China pharmaceuti...

China Chinese Patent Medicine Industry Report, 2013-2016

Chinese patent medicine refers to the certain dosage forms of medicine, under the guidance of TCM (traditional Chinese medicine) theory, made from traditional Chinese medicinal materials in accordance...

Global and China Insulin Industry Report, 2013-2017

As the third largest human health disease following neoplastic disease, cardiovascular and cerebrovascular diseases, the number of diabetic patients has continued growing from 246 million in 2007 to 3...

China Large Volume Parenteral (LVP) Industry Report, 2013-2015

Under the context of China's medical reform and sustainable development of the pharmaceutical market, the output and demand of Large Volume Parenteral (LVP) which is one of the top five Chinese prepar...

China Vitamin Industry Report, 2012-2015

As a great power of vitamin production and export, China has long been known as the world’s vitamin production base. In recent years, its vitamin exports on external demand accounted for about 80% of ...

2005- All Rights Reserved 京ICP备05069564号-1 京公网安备1101054484号